Anticipatory nausea: current landscape and future directions

Ahrari, Soha; Chow, Ronald; Goodall, Shannon; DeAngelis, Carlo

doi:10.21037/apm.2016.10.01

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can negatively impact the quality of life of patients and also place patients at increased risk of treatment nonadherence [2]. Furthermore, poorly controlled CINV increases the risk of CINV during subsequent treatment cycles and also the risk of developing anticipatory nausea [3]. It is therefore prudent to provide effective antiemetics to patients undergoing emetogenic therapies.…”

Section: Introductionmentioning

confidence: 99%

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis

Chow

Navari

Terry

et al. 2021

Support Care Cancer

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis

Chow

Navari

Terry

et al. 2021

Support Care Cancer

Self Cite

View full text Add to dashboard Cite

“…It can negatively impact quality of life for patients, and also place patients at increased risk of treatment nonadherence 2 . Furthermore, poorly controlled CINV increases the risk of CINV during subsequent treatment cycles and also the risk of developing anticipatory nausea 3 . It is therefore prudent to provide effective antiemetics to patients undergoing emetogenic therapies.…”

Section: Introductionmentioning

confidence: 99%

Olanzapine 5mg vs 10mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting – A Network Meta-Analysis

Chow

Navari

Terry

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction: Olanzapine administered at a 10mg dosage for prophylaxis of chemotherapy-induced nausea and vomiting may be associated with fatigue, drowsiness and reduced general activity. Therefore, a 5mg dose may be preferred, to reduce the occurrence of adverse events. The aim of this study was to conduct a network meta-analysis, and report on the efficacy of olanzapine administered at 5mg, relative to when administered at 10 mg. Methods: We used previously-published data from the systematic review by Chow et al which identified 17 adult trials which used 10mg doses, 3 which used 5mg doses, and 1 which used a mix of 5 and 10mg doses. A multivariate network meta-analysis using a restricted maximum likelihood model was used. Results: The complete response rate in the acute phase is not statistically different, between 5mg and 10mg doses of olanzapine – RR 0.97, 95% CI: 0.83 – 1.13. Additionally, in the overall phase, 5mg olanzapine is similarly as efficacious as 10mg olanzapine – RR 0.95, 95% CI: 0.56 – 1.60. Evaluation of data demonstrated that there was inadequate information to compare the toxicities of the two doses. Conclusion: Our analyses support individual published trials, and the rationale for future trials to compare 5mg to 10mg olanzapine regimens in head-to-head comparisons.

show abstract

Cancer-Related Eating Problems

Krautbauer

Drossel

2017

Principle-Based Stepped Care and Brief Psychotherapy for Integrated Care Settings

View full text Add to dashboard Cite

Anticipatory nausea: current landscape and future directions

Cited by 3 publications

References 0 publications

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis

Olanzapine 5mg vs 10mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting – A Network Meta-Analysis

Cancer-Related Eating Problems

Contact Info

Product

Resources

About